94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Victoria Navarro-Compán1†
Luis Puig2†
Silvia Vidal3
Julio Ramírez4
Mar Llamas-Velasco5
Cristina Fernández-Carballido6Raquel Almodóvar7
José Antonio Pinto8
Eva Galíndez-Aguirregoikoa9Pedro Zarco7
Beatriz Joven10Jordi Gratacós11Xavier Juanola12
Ricardo Blanco13
Salvador Arias-Santiago14,15,16
Jesús Sanz Sanz17
Rubén Queiro18*‡
Juan D. Cañete4*‡- 1Department of Rheumatology, Hospital Universitario La Paz, IdiPaz, Madrid, Spain
- 2Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 3Immunology-Inflammatory Diseases, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain
- 4Arthritis Unit, Department of Rheumatology, Hospital Clínic and Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- 5Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain
- 6Department of Rheumatology, Hospital Universitario San Juan de Alicante, Alicante, Spain
- 7Department of Rheumatology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
- 8Department of Rheumatology, Complejo Hospitalario Universitario de A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain
- 9Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain
- 10Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain
- 11Department of Rheumatology, Medicine Department Autonomus University of Barcelona (UAB), I3PT, University Hospital Parc Taulí Sabadell, Barcelona, Spain
- 12Department of Rheumatology, University Hospital Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain
- 13Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- 14Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain
- 15Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
- 16Department of Dermatology, Facultad de Medicina, Universidad de Granada, Granada, Spain
- 17Department of Rheumatology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain
- 18Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
A Corrigendum on
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases
By Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, Almodóvar R, Pinto JA, Galíndez-Aguirregoikoa E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias-Santiago S, Sanz J, Queiro R and Cañete JD (2023) Front. Immunol. 14:1191782. doi: 10.3389/fimmu.2023.1191782
In the published article, there was an error in Table 1 as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published.
Also, there is no data regarding clinical studies using tildrakizumab for IBD, so the color has been changed to yellow.
The legend has been modified for clarification. The changes include the modification from “Green: Shown efficacy” to “Green: approved or shown efficacy in phase 3 clinical trials”.
The corrected Table 1 and its caption “Available therapies targeting IL-17 and IL-23 in IMIDs” appear below.
TABLE 1
Table 1 Available therapies targeting IL-17 and IL-23 in IMIDs.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: IL-17A, IL-17F, IL-23, spondyloarthritis, Th17 cells, MAIT cells, γδ T cells, psoriasis
Citation: Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, Almodóvar R, Pinto JA, Galíndez-Aguirregoikoa E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias-Santiago S, Sanz JS, Queiro R and Cañete JD (2023) Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front. Immunol. 14:1332177. doi: 10.3389/fimmu.2023.1332177
Received: 02 November 2023; Accepted: 13 November 2023;
Published: 22 November 2023.
Edited and Reviewed by:
Gerald Nabozny, Boehringer Ingelheim, United StatesCopyright © 2023 Navarro-Compán, Puig, Vidal, Ramírez, Llamas-Velasco, Fernández-Carballido, Almodóvar, Pinto, Galíndez-Aguirregoikoa, Zarco, Joven, Gratacós, Juanola, Blanco, Arias-Santiago, Sanz, Queiro and Cañete. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Juan D. Cañete, amNhbmV0ZUBjbGluaWMuY2F0; Rubén Queiro, cnViZW5xdWU3QHlhaG9vLmVz
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship